$144.185M Market Capitalization Numinus Wellness Inc. (NUMI.T) announced today that it has completed key steps in preparation for enrollment at the Company’s clinics participating in a “multi-site open-label extension…
numinus
$140.123M Market Capitalization Numinus Wellness Inc. (NUMI.T) announced today that it has formally submitted its clinical trial application (CTA) to Health Canada for its Phase 1 study, HOPE, on…
We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely sure what an ETF…
“In business, cash is oxygen” – Gary Vaynerchuk Psychedelics is a cash-intensive business. Earlier in the week, I wrote about how clinical trials alone cost companies tens, sometimes…
Numinus Wellness (NUMI.V) announced that Health Canada has cleared their MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The study is being…
Numinus Wellness (NUMI.V) announced they are going to acquire Neurology Centre of Toronto (NCT), pursuant to a purchase agreement from July 2, 2021. To acquire the centre, Numinus will…
Numinus Wellness (NUMI.V) and Optimi Health (OPTI.C) announced they have submitted a pre-clinical trial application to Health Canada. The application was submitted through Impact Clinical Trials Accelerator at the…
“Life is too short to be small.” – Tim Ferriss, The 4-Hour Workweek Every psychedelics company starts its investor deck off with a fact about the quickly changing regulatory…
Numinus (NUMI.V) is gaining somewhat of a cult-like following among retail investors. People see an undervalued company with competitive advantages, and from an ethics standpoint, a company conducting…